BMY News & Events

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.NEW UNIT:Francessca Vasquez, Vice President of Frontier AI Engineering and Services, AWS, said in a blog post, "I'm excited to announce that we are meeting that demand by creating a dedicated AWS Forward Deployed Engineering organization. Backed by a $1B investment, the AWS FDE model is different in three key ways: it is agentic-first, it compresses timelines from months to days, and it is designed so customers are self-sufficient when a deployment ends. AWS FDE embeds AWS frontier teams-working with purpose-built agents-directly inside customer teams. These experienced engineers, many of whom build our AWS AI services, partner with a customer's business, engineering, and security teams to build and deploy production AI systems with their data, governance, and processes. Unlike traditional consulting that assesses, recommends, and treats each deployment as a standalone project, AWS FDE builds for the long term. Customers leave AWS FDE deployments with both new solutions and new engineering capabilities. Along with agentic systems running in their own AWS environment, they gain lasting AI skills, workflows, and patterns they can use to innovate independently. Deployments are structured around shared goals and business results, not billable hours. When customers succeed, we succeed."CLAUDE SCIENCE:Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang. Publicly traded companies in the pharmaceutical space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.CLAUDE APPS GETAWAY:Anthropic introduced the Claude apps gateway for Amazon Bedrock and Google Cloud. Previously, running Claude Code on these platforms has meant provisioning a cloud credential per developer, manually pushing settings to every laptop, and standing up separate tooling to see per-developer spend. The gateway is a self-hosted control plane that gives you corporate SSO login, centrally enforced policy, role-based access, and per-user cost attribution for Claude Code. The gateway is run as a single stateless container deployed on Linux and backed by a PostgreSQL database. It holds your upstream credential, authenticates developers against your identity provider, distributes and enforces managed settings, and reports per-user usage to a collector you operate. Onboarding a developer means adding them to your Identity Provider. Offboarding means removing them.Meanwhile, Anthropic said that, starting Monday, Claude models are generally available in MicrosoftFoundry, hosted on Azure. "Claude runs in your Azure environment with the authentication, billing, and governance controls your teams already use," Anthropic said. "You can choose where inference is processed, including a US data zone for teams with data residency requirements. Anthropic operates the inference and is the data processor."

Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang report. Publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

RBC Capital analyst Trung Huynh tells investors in a research note that CMS on Friday proposed making the Medicare Drug Price Negotiation Program permanent beginning in 2029 and tightening rules around fixed-combination lifecycle strategies, creating headline risk for Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY), Merck (MRK), and Regeneron (REGN), although legal challenges, statutory exemptions, and portfolio diversification are expected to limit the practical impact.

A new proposal from the Centers for Medicare & Medicaid Services would establish a permanent framework for the Medicare Drug Price Negotiation Program, creating a more transparent and sustainable process for lowering drug costs for millions of Medicare beneficiaries. The proposed rule would also create greater long-term certainty for drug manufacturers that participate in negotiations. It includes policies for negotiating and renegotiating high-cost, single-source drugs beginning with initial price applicability year 2029, while continuing to support innovation and strengthen the program. "This proposed rule lowers drug prices for seniors and ensures continued savings," said CMS Administrator Dr. Mehmet Oz. "We are moving from annual updates to a permanent, predictable framework. This approach puts patients first, strengthens Medicare, and protects the innovation pipeline that delivers future cures." CMS will select up to 20 additional negotiation-eligible drugs covered under Part D and/or payable under Part B for this fourth cycle of negotiations and subsequent cycles of the Negotiation Program. As required by law, the Negotiation Program must also transition from being implemented through guidance to being codified in regulations as a durable, long-term framework. This rule also would create certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program. The rule also proposes a narrow modification of the policy used to identify qualifying single source drugs to address potential program integrity concerns posed by certain new formulations. In addition to codifying the existing program, CMS is proposing to implement the Temporary Floor for Small Biotech Drugs, as required by law, which limits CMS from offering or agreeing to a counteroffer for a maximum fair price for Small Biotech Drugs below the floor for certain eligible drugs during initial price applicability years 2029 and 2030. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).